trial · primary record
hu1418K322A + Temozolomide + Irinotecan
High-Risk Neuroblastoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 144 |
| Primary completion | 2031-03 |
| Primary endpoint | Overall response rate (ORR) |
| Registry ID | NCT07549321 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:06.260Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07549321
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.